Multimodality Noninvasive Imaging Demonstrates In Vivo Cardiac Regeneration After Mesenchymal Stem Cell Therapy

Amado, Luciano C.; Schuleri, Karl H.; Saliaris, Anastasios; Boyle, Andrew; Helm, Robert H.; Oskouei, Behzad; Centola, Marco; Eneboe, Virginia; Young, Randell G.; Lima, João A.C.; Lardo, Albert C.; Heldman, Alan W.; Hare, Joshua M.

doi:10.1016/j.jacc.2006.06.073

Cited by 149 publications

(96 citation statements)

References 41 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MSC are a nontumorigenic, adherent fraction of heterogeneous cells that exhibit spindlelike morphology and clonogenic growth and express CD90, CD105, and CD73 but not CD34 or CD45 (5). After acute MI, MSC reverse both pathologic remodeling and scar size and enhance both ventricular mass and ejection fraction (6,7). Overall, MSC have proven to be a safe, attractive, and potent candidate for CCT.…”

Section: Advances In Knowledgementioning

confidence: 99%

Multimodality Molecular Imaging of Cardiac Cell Transplantation: Part I. Reporter Gene Design, Characterization, and Optical in Vivo Imaging of Bone Marrow Stromal Cells after Myocardial Infarction

Parashurama

Ahn²,

Ziv

et al. 2016

Radiology

View full text Add to dashboard Cite

4 The complete list of authors is at the end of this article.q RSNA, 2016 Purpose:To use multimodality reporter-gene imaging to assess the serial survival of marrow stromal cells (MSC) after therapy for myocardial infarction (MI) and to determine if the requisite preclinical imaging end point was met prior to a follow-up large-animal MSC imaging study. Materials and Methods:Animal studies were approved by the Institutional Administrative Panel on Laboratory Animal Care. Mice (n = 19) that had experienced MI were injected with bone marrow-derived MSC that expressed a multimodality triple fusion (TF) reporter gene. The TF reporter gene (fluc2-egfp-sr39ttk) consisted of a human promoter, ubiquitin, driving firefly luciferase 2 (fluc2), enhanced green fluorescent protein (egfp), and the sr39tk positron emission tomography reporter gene. Serial bioluminescence imaging of MSC-TF and ex vivo luciferase assays were performed. Correlations were analyzed with the Pearson product-moment correlation, and serial imaging results were analyzed with a mixed-effects regression model.

show abstract

Section: Advances In Knowledgementioning

confidence: 99%

Multimodality Molecular Imaging of Cardiac Cell Transplantation: Part I. Reporter Gene Design, Characterization, and Optical in Vivo Imaging of Bone Marrow Stromal Cells after Myocardial Infarction

Parashurama

Ahn²,

Ziv

et al. 2016

Radiology

View full text Add to dashboard Cite

show abstract

“…These measurements allow for calculation of left-ventricular ejection volume, fractional shortening, and mass. Three-dimensional imaging using cardiac magnetic resonance or multidetector computerized tomography permits similar measurements but with a higher degree of precision and accuracy due to improved temporal and spatial resolution that also offers detailed examination of changes in tissue morphology (42,93).…”

Section: Hemodynamic Assessmentmentioning

confidence: 99%

Stem cell therapy for cardiac disease

2012

View full text Add to dashboard Cite

“…In 2006, Amado et al 11 used magnetic resonance imaging to monitor myocardial repair following mesenchymal stem cell therapy in a swine model, and found regeneration of viable tissue with contractile function in a previously fibrotic area.…”

Section: State Of the Art Preclinical Researchmentioning

confidence: 99%

Mesenchymal stem cell therapy in heart disease

Lopes

Fiarresga

Cunha

et al. 2013

Revista Portuguesa de Cardiologia (English Edition)

View full text Add to dashboard Cite

Cardiovascular disease is among the main causes of mortality and morbidity worldwide. Despite significant advances in medical and interventional therapy, the prognosis of conditions such as ischemic heart disease is still dismal. There is thus a need to investigate new therapeutic tools, one of which is stem cell therapy. Hematopoietic stem cells are the most studied type, and the fact that their biology is relatively well understood has led to their being used in preclinical research and clinical trials. However, the results of some of these studies have been controversial, which has opened the way for studies on other cell types, such as mesenchymal stem cells. These cells have immunomodulatory properties which suggest that they have therapeutic potential in cardiology. In the present article, the authors review the state of the art regarding mesenchymal stem cells, from basic and translational research to their use in clinical trials on ischemic heart disease, heart failure and arrhythmias, and discuss possible future uses. © 2012 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L. All rights reserved. PALAVRAS-CHAVE Terapia celular cardíaca com células mesenquimatosasResumo A doença cardiovascular é uma das principais causas de mortalidade e morbilidade em todo o mundo e, apesar de os avanços na terapêutica médica e intervenção percutânea, o prognóstico de doenças como a cardiopatia isquémica e o pós-enfarte do miocárdio continuam a ser consideravelmente inferiores ao desejado. Essa situação justifica a aposta na investigação de novas ferramentas terapêuticas, como é o caso da terapia com células estaminais. O conhecimento mais vasto das células de linhagem hematopoiética levou à sua utilização numa primeira fase, tanto em investigação pré-clínica como clínica. A existência de alguns resultados controversos e de uma melhoria correspondente às expectativas iniciais abriu a caminho a outros tipos celulares com potencial terapêutico, como é o caso das células precursoras do mesênquima. Estas células têm características imunomoduladoras que lhes conferem um racional de utilidade terapêutica em várias áreas da Cardiologia. Neste artigo, os autores efetuam a revisão do estado da arte relativo à utilização de células precursoras do mesênquima, desde a sua investigação ଝ Please cite this article as: Lopes, JP; Terapia celular cardíaca com células mesenquimatosas. Rev Port Cardiol 2012. http://dx

show abstract

Multimodality Noninvasive Imaging Demonstrates In Vivo Cardiac Regeneration After Mesenchymal Stem Cell Therapy

Cited by 149 publications

References 41 publications

Multimodality Molecular Imaging of Cardiac Cell Transplantation: Part I. Reporter Gene Design, Characterization, and Optical in Vivo Imaging of Bone Marrow Stromal Cells after Myocardial Infarction

Multimodality Molecular Imaging of Cardiac Cell Transplantation: Part I. Reporter Gene Design, Characterization, and Optical in Vivo Imaging of Bone Marrow Stromal Cells after Myocardial Infarction

Stem cell therapy for cardiac disease

Mesenchymal stem cell therapy in heart disease

Contact Info

Product

Resources

About